IntraBio Secures European Approval for AQNEURSA® in Niemann-Pick Type C Treatment
Event summary
- The European Commission granted marketing authorization for AQNEURSA® (levacetylleucine) to treat neurological manifestations of Niemann-Pick Type C (NPC) disease.
- Approval covers adults and children aged 6+ weighing at least 20 kg, usable alone or with miglustat.
- Phase III trial data showed statistically significant improvements in neurological signs after 12 weeks.
- Long-term extension phase sustained benefits, suggesting neuroprotective effects over time.
The big picture
This approval solidifies IntraBio’s position as a key player in treating rare neurological diseases, particularly those with limited therapeutic options. The decision underscores the growing recognition of targeted metabolic therapies for lysosomal storage disorders. With NPC affecting approximately 1 in 100,000 live births, this milestone could expand IntraBio's market reach and reinforce its pipeline strategy in neurodegenerative conditions.
What we're watching
- Regulatory Strategy
- Whether IntraBio can replicate this success in other major markets, particularly the U.S., where it already has approval.
- Commercial Execution
- The pace at which IntraBio can establish AQNEURSA® as a standard treatment for NPC across Europe.
- Pipeline Progress
- How the company's parallel efforts in Ataxia-Telangiectasia (A-T) will impact its broader rare disease portfolio.
Related topics